Found: 28
Select item for more details and to access through your institution.
Tratamiento acortado a 16 semanas en paciente con infección por genotipo 2 del virus de hepatitis C. Reporte de un caso y revisión de la literature.
- Published in:
- Revista Colombiana de Gastroenterología, 2014, v. 29, n. 3, p. 270
- By:
- Publication type:
- Article
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon α-2a (40KD) (PEGASYS<sup>®</sup>) plus ribavirin (COPEGUS<sup>®</sup>) for 16 or 24 weeks.
- Published in:
- Liver International, 2009, v. 29, n. 2, p. 237, doi. 10.1111/j.1478-3231.2008.01859.x
- By:
- Publication type:
- Article
Prevalence of non‐alcoholic fatty liver and liver fibrosis in patients with moderate–severe psoriasis: A cross‐sectional cohort study.
- Published in:
- Australasian Journal of Dermatology, 2020, v. 61, n. 2, p. 105, doi. 10.1111/ajd.13175
- By:
- Publication type:
- Article
Real‐life effectiveness of sofosbuvir/velpatasvir/voxilaprevir in hepatitis C patients previously treated with sofosbuvir/velpatasvir or glecaprevir/pibrentasvir.
- Published in:
- Alimentary Pharmacology & Therapeutics, 2024, v. 60, n. 2, p. 201, doi. 10.1111/apt.18020
- By:
- Publication type:
- Article
Prediction of Week 4 Virological Response in Hepatitis C for Making Decision on Triple Therapy: The Optim Study.
- Published in:
- PLoS ONE, 2015, v. 10, n. 3, p. 1, doi. 10.1371/journal.pone.0122613
- By:
- Publication type:
- Article
Definite and indeterminate nonalcoholic steatohepatitis share similar clinical features and prognosis: A longitudinal study of 1893 biopsy‐proven nonalcoholic fatty liver disease subjects.
- Published in:
- Liver International, 2021, v. 41, n. 9, p. 2076, doi. 10.1111/liv.14898
- By:
- Publication type:
- Article
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild‐moderate fibrosis: Results from a real‐world cohort.
- Published in:
- Liver International, 2019, v. 39, n. 1, p. 90, doi. 10.1111/liv.13950
- By:
- Publication type:
- Article
Serum biomarkers can predict a change in liver fibrosis 1 year after lifestyle intervention for biopsy-proven NASH.
- Published in:
- Liver International, 2017, v. 37, n. 12, p. 1887, doi. 10.1111/liv.13480
- By:
- Publication type:
- Article
High efficacy of Sofosbuvir plus Simeprevir in a large cohort of Spanish cirrhotic patients infected with genotypes 1 and 4.
- Published in:
- Liver International, 2017, v. 37, n. 12, p. 1823, doi. 10.1111/liv.13470
- By:
- Publication type:
- Article
Simeprevir and daclatasvir for 12 or 24 weeks in treatment-naïve patients with hepatitis C virus genotype 1b and advanced liver disease.
- Published in:
- Liver International, 2017, v. 37, n. 9, p. 1304, doi. 10.1111/liv.13376
- By:
- Publication type:
- Article
Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study.
- Published in:
- Liver International, 2015, v. 35, n. 2, p. 448, doi. 10.1111/liv.12703
- By:
- Publication type:
- Article
Multicenter randomized study comparing initial daily induction with high dose lymphoblastoid interferon vs. standard interferon treatment for chronic hepatitis c.
- Published in:
- Journal of Medical Virology, 2001, v. 64, n. 4, p. 460, doi. 10.1002/jmv.1072
- By:
- Publication type:
- Article
Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.
- Published in:
- 2004
- By:
- Publication type:
- journal article
Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C.
- Published in:
- Annals of Internal Medicine, 2004, v. 140, n. 5, p. 346, doi. 10.7326/0003-4819-140-5-200403020-00010
- By:
- Publication type:
- Article
Optimized virologic response in hepatitis C virus genotype 4 with peginterferon-alpha2a and ribavirin.
- Published in:
- 2004
- By:
- Publication type:
- Letter
Peginterferon α-2a (40kD) [Pegasys[sup ®]] Improves HR-QOL Outcomes Compared with Unmodified Interferon α-2a [Roferon[sup ®]-A]: In Patients with Chronic Hepatitis C.
- Published in:
- PharmacoEconomics, 2003, v. 21, n. 5, p. 341, doi. 10.2165/00019053-200321050-00005
- By:
- Publication type:
- Article
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C.
- Published in:
- 2003
- By:
- Publication type:
- journal article
One-step diagnosis strategy together with multidisciplinary telematics referral perform an effective approach for identifying and treating patients with active Hepatitis C infection.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2022, v. 27, n. 1, p. 1, doi. 10.1016/j.aohep.2021.100542
- By:
- Publication type:
- Article
High efficacy and safety of triple therapy in HCV genotype 1 and moderate fibrosis: a multicenter study of clinical practice in Spain.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2015, v. 14, n. 4, p. 477, doi. 10.1016/s1665-2681(19)31169-x
- By:
- Publication type:
- Article
PNPLA3 rs738409 causes steatosis according to viral & IL28B genotypes in hepatitis C.
- Published in:
- Annals of Hepatology: Official Journal of the Mexican Association of Hepatology, 2014, v. 13, n. 4, p. 356, doi. 10.1016/s1665-2681(19)30842-7
- By:
- Publication type:
- Article
Simeprevir with peginterferon α-2a/ribavirin for chronic hepatitis C virus genotype 1 infection in treatment-experienced patients: an open-label, rollover study.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Can secukinumab improve liver fibrosis? A pilot prospective study of 10 psoriatic patients.
- Published in:
- Dermatologic Therapy, 2021, v. 34, n. 5, p. 1, doi. 10.1111/dth.15065
- By:
- Publication type:
- Article
Reassessing HIV Detection Strategies: An Analysis of Opportunistic Screening vs. Indicator-Condition-Driven Diagnosis in Valencia, Spain.
- Published in:
- Journal of Community Health, 2024, v. 49, n. 4, p. 748, doi. 10.1007/s10900-024-01326-9
- By:
- Publication type:
- Article
The biochemical pattern defines MASLD phenotypes linked to distinct histology and prognosis.
- Published in:
- Journal of Gastroenterology, 2024, v. 59, n. 7, p. 586, doi. 10.1007/s00535-024-02098-8
- By:
- Publication type:
- Article
No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
- Published in:
- PLoS ONE, 2018, v. 13, n. 7, p. 1, doi. 10.1371/journal.pone.0199198
- By:
- Publication type:
- Article
Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α-2a (40 kDa) plus ribavirin: Impact on health-related quality of life.
- Published in:
- Journal of Gastroenterology & Hepatology, 2006, v. 21, n. 2, p. 406, doi. 10.1111/j.1440-1746.2005.04059.x
- By:
- Publication type:
- Article
Importance of Host Genetic Factors HLA and IL28B as Predictors of Response to Pegylated Interferon and Ribavirin.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2011, v. 106, n. 7, p. 1246, doi. 10.1038/ajg.2011.82
- By:
- Publication type:
- Article
Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis.
- Published in:
- American Journal of Gastroenterology (Springer Nature), 2004, v. 99, n. 11, p. 2150, doi. 10.1111/j.1572-0241.2004.40416.x
- By:
- Publication type:
- Article